Context Therapeutics Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. Context is a clinical-stage biopharmaceutical company developing therapies focused primarily on women’s cancers. It reported no product revenue and operates as a single business segment.
Key financial results
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development | $2.08 million | $0.74 million | $4.95 million | $2.51 million |
| General and administrative | $1.97 million | $0.83 million | $6.05 million | $1.83 million |
| Operating loss | $4.05 million | $1.57 million | $11.50 million | $7.43 million |
| Net loss | $3.85 million | $1.44 million | $11.28 million | $7.37 million |
| Operating cash used | Not separately stated | Not separately stated | $9.62 million | $3.84 million |
At September 30, 2022, cash and cash equivalents were $39.43 million, versus $49.64 million at December 31, 2021. Total assets were $42.08 million; current liabilities were $4.01 million, and stockholders’ equity was $38.07 million. The company reported no borrowings or other debt at quarter-end; liabilities primarily comprised accounts payable, accrued expenses, and lease obligations. Gross and operating margins are not meaningful because the company had no revenue.
Changes and cash use
- Q3 net loss increased $2.41 million, or 167%, year over year. R&D increased 181%, largely due to ONA-XR manufacturing and clinical-trial costs, including preparation for the ELONA trial. G&A increased 138%, reflecting higher compensation and share-based compensation, insurance, and public-company costs.
- For the first nine months, net loss increased $3.91 million, or 53%. R&D rose 97%, driven mainly by ONA-XR development and personnel; G&A rose 230%, driven by compensation, insurance, and public-company expenses. The lower year-over-year acquired in-process R&D charge partly offset these increases.
- Cash used in investing activities was $0.54 million, including a $0.50 million CLDN6 development milestone payment. Financing activities used $0.10 million, primarily for private-placement offering costs. Cash, cash equivalents, and restricted cash declined $10.26 million during the nine-month period.
Programs, outlook, and risks
- ONA-XR: Investigator-sponsored Phase 2 trials were ongoing. In the endometrial-cancer study, 12 of 25 planned patients were enrolled; preliminary four-month progression-free survival was 77.7% among nine evaluable patients, with no treatment-related serious adverse events reported. The filing cautions that interim results may change. Updated data from two ongoing studies were expected in mid-2023; initial SMILE trial data were expected in December 2022. The company initiated the Menarini-supported ELONA Phase 1b/2 trial in November 2022, with Phase 1b data expected in Q4 2023.
- CLDN6xCD3 bispecific antibody: Candidate selection for IND-enabling studies was expected in December 2022, with an IND submission planned for Q1 2024. A November 7, 2022 Lonza development/manufacturing services agreement and related license were disclosed as subsequent events. Their terms include potential annual payments of less than $500,000 and royalties ranging from 0% to a low-single-digit percentage; certain manufacturing-transfer arrangements could involve a fee of up to £750,000.
- Management expected existing cash to fund operations into Q1 2024, while the financial-statement note also says cash was expected to cover projected operations for at least 12 months from issuance. These are estimates dependent on assumptions; the company expects ongoing losses and says substantial additional financing will be needed. No committed capital sources or credit facility were reported.
- Key risks include clinical and regulatory uncertainty, reliance on third-party manufacturers and research organizations, potential trial delays or cost increases, and the need for future financing, which may dilute shareholders or require granting rights to programs. The company also identified uncertainty about the Inflation Reduction Act’s effect on future pricing and profitability. No material legal proceedings were reported. Management concluded disclosure controls were effective; no material internal-control changes were reported.
Important facts for investors to verify
- Cash runway assumptions and the timing and terms of any future financing.
- Progress, enrollment, safety, and final analyses of ONA-XR trials, including whether preliminary results are confirmed.
- CLDN6 candidate-selection and IND-enabling milestones, and the cost and obligations under the Lonza agreements.
- Potential dilution: 15.97 million common shares were outstanding at November 4, 2022, and 5.86 million warrants were outstanding at September 30, 2022.
- Future milestone, royalty, and manufacturing commitments, including obligations under the Integral Molecular and Tyligand agreements.